Endometrial clinical trials: recruitment closed
ENGOT-en7 / AtTEnd | MaNGO Study |
STATUS: Recruitment completed
SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: A
TITLE: Atezolizumab Trial in Endometrial cancer. Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
ClinicalTrials.gov ID: NCT03603184
MaNGO sites (click to see the list on clinicaltrials.gov)
Sinossi (click to see pdf)
Updates (click to see the Newsletter)
ESMO 2023 (click to see the abstract)
Lancet Oncology Manuscript 2024 (click to see the link)
ENGOT-en15 / GOG-3064
STATUS: Recruitment completed
SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: MITO
ENGOT Model: C
TITLE: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
ClinicalTrials.gov ID: NCT05173987
MaNGO sites (click to see the list)